Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. FLIXABI (infliximab)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

FLIXABI (infliximab)

Medicine - Posted on Nov 07 2016 - Updated on Jun 12 2019
Active substance (DCI)
  • infliximab
history (2)
  • 10/19/16

    FLIXABI (infliximab)

    Avis défavorable au maintien du remboursement en association avec le méthotrexate dans le traitement de la polyarthrite rhum...
    icône flèche
  • 6/29/16

    FLIXABI, biosimilaires d’infliximab, anti-TNF (infliximab)

    Pas d’avantage clinique démontré par rapport à REMICADE (biothérapie de référence) INFLECTRA, REMSIMA et FLIXABI sont des bi...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L04AB02
Manufacturer
BIOGEN FRANCE SAS
Presentation

FLIXABI 100 mg, poudre pour solution à diluer pour perfusion (code CIS : 69531804)
1 Boite de 1 flacon en verre de 100 mg - Code CIP : 34009 550 230 1 2

All our publications
    Autoimmune diseases Drug therapy Esophageal and gastrointestinal diseases Joint and rheumatic diseases Paediatrics Pain - Inflammation Skin and connective tissue diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
Yx9wRf6Ff3TXKfkj